NDATOPICALOINTMENT
Approved
Jan 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
VECTICAL (calcitriol) by Galderma is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 2009.
Drug data last refreshed 3h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VECTICAL is a topical vitamin D3 analog (calcitriol ointment) approved in 2009 for treatment of psoriasis and other dermatologic conditions. It works by binding to vitamin D receptors in skin cells to regulate calcium and phosphorus metabolism and reduce abnormal skin cell proliferation. The active ingredient is calcitriol, the most potent form of vitamin D3.
$0.002BPart D
LOE ApproachingThis product is in late commercial maturity with declining prescription volume ($2M annual spending), suggesting team consolidation and reduced headcount opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on VECTICAL at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.